{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:52:30Z","timestamp":1767192750195,"version":"build-2065373602"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nivolumab is a monoclonal antibody that targets the PD-1 pathway, significantly transforming cancer immunotherapy. However, its use is associated with immune-related adverse events (irAEs), including immune-mediated hepatitis (IMH), which can be severe or even life-threatening. We present a case of an 81-year-old male with gastric cancer and liver metastasis, who demonstrated significant anti-tumor efficacy following nivolumab monotherapy. The patient developed grade 3 IMH during treatment, but after discontinuing the medication and receiving timely treatment, his symptoms improved, and liver biochemical markers declined. Additionally, using the FDA Adverse Event Reporting System (FAERS) database, we analyzed the incidence of hepatitis adverse events caused by different immune checkpoint inhibitors (ICIs) in various age groups of patients to better understand the safety of these drugs in different patient populations.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1663107","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:31:17Z","timestamp":1761111077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab in gastric cancer with liver metastasis complicated by immune-mediated hepatitis: a case report and FAERS database analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yong-Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Lan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Jun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong-Lin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40792-024-01905-x","article-title":"Conversion surgery for gastric remnant cancer with liver metastasis after nivolumab combination chemotherapy achieving pathological complete response: a case report and literature review","volume":"10","author":"Katsumata","year":"2024","journal-title":"Surg Case Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse efects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2019.09.009","article-title":"Immune checkpoint inhibitorrelated luminal GI adverse events","volume":"90","author":"Kr\u00f6ner","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03448-8","article-title":"Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers","volume":"147","author":"Yamamoto","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1093\/oncolo\/oyae056","article-title":"Tumor response predicts survival time of nivolumab monotherapy for advanced gastric cancer: A subgroup analysis of the DELIVER trial (JACCRO GC-08)","volume":"29","author":"Sunakawa","year":"2024","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12876-024-03508-0","article-title":"Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"24","author":"Lei","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B12","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (Version 4.2024)","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12957-020-01954-0","article-title":"Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report","volume":"18","author":"Matsumoto","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40792-018-0479-3","article-title":"Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab","volume":"4","author":"Namikawa","year":"2018","journal-title":"Surg Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40792-023-01668-x","article-title":"Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer","volume":"9","author":"Jun","year":"2023","journal-title":"Surg Case Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s40792-024-01929-3","article-title":"Successful R0 resection after chemotherapy, including nivolumab, for gastric cancer with liver metastases: three case reports","volume":"10","author":"Kawai","year":"2024","journal-title":"Surg Case Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000514396","article-title":"Successful conversion surgery for stage IV gastric cancer after nivolumab monotherapy as third-line chemotherapy","volume":"15","author":"Watanabe","year":"2021","journal-title":"Case Rep Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B22","first-page":"26","article-title":"Consensus on immune-related adverse events of gastrointestinal tumor in China (2023 edition)","volume":"9","year":"2023","journal-title":"J Multidiscip Cancer Manage"},{"key":"B23","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities (Version 1.2025)","year":"2025"},{"key":"B24","volume-title":"Guidelines for the Management of immune Checkpoint Inhibitor-Related Toxicities","year":"2023"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:31:19Z","timestamp":1761111079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1663107"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1663107","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1663107"}}